thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
If it's a legitimate rape, the female body has ways to try to shut the whole thing down." In 2017, Shaw had a supporting role as Gail Hurley in the feature film Stronger, which was directed by David Gordon Green, and starred Jake Gyllenhaal as 2013 Boston Marathon bombing survivor Jeff Bauman. In 2019, it was reported that Shaw is attached to direct an adaption of the Katherine Faw Morris novel Ultraluminous, produced by Steven Soderbergh. In 2020, numerous announcements were made regarding projects Shaw is attached to: she is reported to be writer and executive producer of an HBO series adapting the 1978 Judy Blume novel Wifey, and will direct the first episode; she is reportedly to star in Kill Switch, a film to be directed by Soderbergh; and she is attached to direct an adaption of T Kira Madden's memoir Long Live the Tribe of Fatherless Girls. She is also set to direct a film adaptation of the comic 4 Kids Walk Into a Bank.
== Marketing as dietary supplement == Patrick Arnold reintroduced methylhexanamine in 2006 as a dietary supplement, after the final ban of ephedrine in the United States in 2005. Arnold introduced it under the trademarked name Geranamine, a name held by his company, Proviant Technologies. A large number of supplements focusing on fat loss and workout energy (thermogenic or general-purpose stimulants) used the ingredient in concert with other substances such as caffeine, a combination similar to the combination of ephedrine and caffeine. Methylhexanamine-containing supplements sometimes list "geranium oil" or "geranium extract" as a source of methylhexanamine. However, geranium oils do not contain methylhexanamine, and the methylhexanamine in these supplements is added in the form of synthetic material. A variety of studies have explored the possibility that DMAA is found in some types of geraniums, but at present, high quality evidence of DMAA's presence in plants is lacking. Methylhexanamine is synthesized by reacting 4-methylhexan-2-one with hydroxylamine, which converts the 4-methylhexan-2-one to 4-methylhexan-2-one oxime, which is reduced via catalytic hydrogenation; the resulting methylhexanamine can be purified by distillation.
Over the years, multiple synthesizers have been developed to assist with automated synthesis, including the Chemspeed Accelerator (SLT106, SLT II, ASW2000, SwingSLT, Autoplant A100, and SLT100), the Symyx system, and Freeslate ScPPR. Recently, researchers have investigated the optimization of these methods for controlled/living radical polymerization (CLRP), which faces issues with oxygen intolerance. This research has led to the development of oxygen-tolerant CLRP, including with the use of enzyme degassing of RAFT (Enz-RAFT), atom-transfer radical (ATRP) that possesses tolerance to air, and photoinduced electron/energy transfer–RAFT (PET–RAFT) polymerization. Through the use of liquid-handling robots, Tamasi et al. demonstrated the use of automated synthesis with executing multi-step procedures, enabling the reactions to investigate more elaborate schemes, such as with scale and complexity. Lee Cronin and his team have developed a modular synthesis machine called the chemputer which uses a dedicated programming language for chemical synthesis.
Genealogy was another ethnic marker. While it was likely that Israelite identity was not exclusively based on blood descent, the Israelites used genealogical self-definition to engage in cultural narcissism, though also in self-representation of impropriety and guilt, as shown in the story of their occasionally morally challenging ancestor, Jacob, a man of blessing and promise but also one who "suffers for his triumphs and pays a price for taking the name 'Israel'". This ambiguous characterization foreshadows "the complexities of the Jewish soul". Names were significant in Israelite culture and indicated one's destiny and inherent character. Thus, a name change indicated a 'divine transformation' in one's 'destines, characters and natures'. These beliefs aligned with the Near Eastern cultural milieu, where names were 'intimately bound up with the very essence of being and inextricably intertwined with personality'. In terms of appearance, rabbis described the Biblical Jews as being "midway between black and white" and having the "color of the boxwood tree". Assuming Yurco's debated claim that the Israelites are depicted in reliefs from Merneptah's temple at Karnak is correct, the early Israelites may have wore the same attire and hairstyles as non-Israelite Canaanites. Dissenting from this, Anson Rainey argued that the Israelites in the reliefs looked more similar to the Shasu. Based on biblical literature, it is implied that the Israelites distinguished themselves from peoples like the Babylonians and Egyptians by not having long beards and chin tufts.
It was determined that subjects that received three daily doses of 40 micrograms/kg demonstrated adequate production of epithelial cells in the buccal mucosa. Predicted elevation in amylase and lipase were also determined. Study 20010192 (Randomized, double-blind, placebo-controlled, dose-escalation). Intended to determine safety and tolerability, pharmacokinetic and pharmacodynamics properties of the drug versus a placebo by utilization of a single IV dose (ranging from 60 to 250 micrograms/kg) in 84 healthy volunteers. It was determined that after the first 30 minutes (after IV dose was administered) a rapid decline in concentration occurred, followed by a subsequent plateau once 1.5 hours had been achieved. A decline in concentration was consistently observed once six hours post-dose had been reached. It was also noted that with a four-fold increase in dose, a three-fold increase in AUC was achieved. Half-life values of 4–6 hours were noted; extravascular distribution of the drug was noted as well.
Sources: en.wikipedia.org
=== Invention === In 1966 (1966) Sato Foods Industries Co., Ltd. invented alcohol pulverization. Sato is a food additives and seasoning manufacturer in Aichi Prefecture in Japan. (ja:佐藤食品工業 (愛知県)) A year later, in 1967, Sato began production and sales of various kinds of "high content alcohol powder Alcock" ("高含度アルコール粉末「アルコック」"). On 15 January 1974, a practical manufacturing process for alcohol powder was patented by Sato. Sato has patented the process in 17 countries around the world. In the 1970s Sato began promoting powdered alcohol in the United States. Test sales began in 1977 under the trade name "SureShot". The product "Palcohol" was announced for future release in the U.S. in 2015. In Turkey, on November 21, 1973, a former chemist named İsmail Serin invented a powdered version of rakı, a traditional Turkish anise-flavored alcoholic beverage.
An animal study comparing the effectiveness of cinnarizine and flunarizine (a derivative of cinnarizine that is 2.5-15 times stronger for treatment of transient global cerebral ischemia), it was found that cinnarizine helped to improve the functional abnormalities of ischemia, but did not help with damage to the neurons. Flunarizine offered more neuronal protection, but was less effective in treating subsequent behavioral changes. Cinnarizine has also been found to be a valuable second-line treatment for idiopathic urticarial vasculitis.
The efferent leg of the peripheral nervous system is responsible for conveying commands to the muscles and glands, and is ultimately responsible for voluntary movement. Nerves move muscles in response to voluntary and autonomic (involuntary) signals from the brain. Deep muscles, superficial muscles, muscles of the face and internal muscles all correspond with dedicated regions in the primary motor cortex of the brain, directly anterior to the central sulcus that divides the frontal and parietal lobes. In addition, muscles that react to reflexive nerve stimuli do not always send signals all the way to the brain. In this case, the signal from the afferent fiber does not reach the brain, but produces the reflexive movement by direct connections with the efferent nerves in the spine. However, the majority of muscle activity is volitional, and the result of complex interactions between various areas of the brain like the basal ganglia, thalamus, cerebellum, and other neuron groups in the midbrain and brain stem. Nerves that control skeletal muscles in mammals correspond with neuron groups along the primary motor cortex of the brain's cerebral cortex. Commands are routed through the basal ganglia and are modified by input from the cerebellum before being relayed through the pyramidal tract to the spinal cord and from there to the motor end plate at the muscles. Along the way, feedback, such as that of the extrapyramidal system contribute signals to influence muscle tone and response.
Lipid profiling is a targeted metabolomics platform that provides a comprehensive analysis of lipid species within a cell or tissue. Profiling based on electrospray ionization tandem mass spectrometry (ESI-MS/MS) is capable of providing quantitative data and is adaptable to high throughput analyses. The powerful approach of transgenics, namely deletion and/or overexpression of a gene product coupled with lipidomics, can give valuable insights into the role of biochemical pathways. Lipid profiling techniques have also been applied to plants and microorganisms such as yeast. A combination of quantitative lipidomic data in conjunction with the corresponding transcriptional data (using gene-array methods) and proteomic data (using tandem MS) enables a systems biology approach to a more in-depth understanding of the metabolic or signaling pathways of interest.
LifeAct is a 17 amino acid recombinant peptide that stains filamentous actin (F-actin) structures of eukaryotic living or fixed cells. There are several types and combinations of LifeAct that can be utilized depending on the cell type, protocol, and purpose of the analysis.
Sources: en.wikipedia.org
== Scientific contributions == Meir Wilchek is known for his research in the field of biorecognition or affinity phenomenon, and its various application, e.g. for affinity chromatography, affinity labeling, affinity therapy, and the avidin-biotin system. The avidin-biotin complex is the highest affinity interaction in nature, and its utilization to biochemistry integrates all of the former approaches. Other contributions include conversion of serines to cysteines, and was the first to prove experimentally the equation of Forster on dependence of energy transfer on distance, an approach known today as FRET. He also studied the fine structure of these chromophores using circular dichroism. More recently, he participated in a research team who studied how garlic works at the molecular level, thanks to a unique biotechnological procedure for producing large quantities of pure allicin, garlic's main biologically active component.
== Receptors == Relaxin interacts with the relaxin receptor LGR7 (RXFP1) and LGR8 (RXFP2), which belong to the G protein-coupled receptor superfamily. They contain a heptahelical transmembrane domain and a large glycosylated ectodomain, distantly related to the receptors for the glycoproteohormones, such as the LH-receptor or FSH-receptor. Relaxin receptors have been found in the heart, smooth muscle, the connective tissue, and central and autonomous nervous system.
He had treated it as a rapid interconversion between two structures, each with alternating single and double bonds, but with the double bonds of one structure in the locations where the single bonds were in the other. Pauling showed that a proper description based on quantum mechanics was an intermediate structure which was a blend of each. The structure was a superposition of structures rather than a rapid interconversion between them. The name "resonance" was later applied to this phenomenon. In a sense, this phenomenon resembles those of hybridization and also polar bonding, both described above, because all three phenomena involve combining more than one electronic structure to achieve an intermediate result.
By 1946, France headed the French Union. As successive governments had forbidden the sending of metropolitan troops, the French Far East Expeditionary Corps (CEFEO) was created in March 1945. The Union gathered combatants from almost all French territories made of colonies, protectorates and associated states (Algeria, Morocco, Madagascar, Senegal, Tunisia, etc.) to fight in French Indochina, which was then occupied by the Japanese. About 325,000 of the 500,000 French troops were Indochinese, almost all of whom were used in conventional units. French West Africa (Afrique Occidentale Française, AOF) was a federation of African colonies. Senegalese and other African troops were sent to fight in Indochina. Some African alumni were trained in the Infantry Instruction Center no.2 (Centre d'Instruction de l'Infanterie no.2) located in southern Vietnam. Senegalese of the Colonial Artillery fought at the siege of Dien Bien Phu. As a French colony (later a full province), French Algeria sent local troops to Indochina including several RTA (Régiment de Tirailleurs Algériens) light infantry battalions. Morocco was a French protectorate and sent troops to support the French effort in Indochina. Moroccan troops were part of light infantry RTMs (Régiment de Tirailleurs Marocains) for the "Moroccan Sharpshooters Regiment".
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.